Market Overview:
The global pancreatic cancer drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of pancreatic cancer, rising awareness about available treatment options, and technological advancements in the field of oncology. Based on type, the global pancreatic cancer drugs market is segmented into drugs approved for pancreatic cancer and abraxane (paclitaxel albumin-stabilized nanoparticle formulation). The drugs approved for pancreatic cancer segment is further sub-segmented into erlotinib hydrochloride, everolimus, 5-FU (fluorouracil injection), gemcitabine hydrochloride, and other drugs. The erlotinib hydrochloride sub-segment is expected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030. This growth can be attributed to its high efficacy as a first line treatment option for patients with advanced or metastatic pancreatic adenocarcinoma. Based on application, the global Pancreatic Cancer Drugs Market is segmented into hospitals and clinics.
Product Definition:
Pancreatic cancer drugs are medications that are used to treat pancreatic cancer. Pancreatic cancer is a type of cancer that begins in the pancreas, a gland located behind the stomach. The most common type of pancreatic cancer is adenocarcinoma, which begins in the cells that line the ducts of the pancreas. Pancreatic cancer drugs may be used to treat tumors that have spread (metastasized) to other parts of the body or to relieve symptoms caused by pancreatic cancer.
Drugs Approved for Pancreatic Cancer:
Pancreatic cancer is a type of cancer that begins in the pancreas. The cause of pancreatic cancer is still unknown, though risk factors include smoking, obesity, and alcohol consumption. Increasing life expectancy has led to an increase in the incidence rate of this disease; thus making it one of the most common types of cancers diagnosed among adults across the world.
Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation):
Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) is a drug that belongs to the family of taxanes. It is an injectable medicine used in the treatment of pancreatic cancer. The drug works by damaging the cancer cells and helps in their destruction. It has been approved by both U.
Application Insights:
The hospital application segment dominated the global pancreatic cancer drugs market in 2017, accounting for over 60.0% share of the total revenue. The dominance is attributed to factors such as availability of advanced healthcare facilities and highly skilled medical personnel in hospitals, which have resulted in a higher incidence rate of pancreatic cancer patients. According to estimates reported by WHO, around 1,000-1,500 people die due to this disease every year worldwide while about 20-30% of these cases are diagnosed at an early stage and could be treated with surgery only; hence offering huge potential markets for pharmaceutical companies manufacturing anti-cancer drugs for this condition.
Pancreatic cancer is one of the most common cancers found among male smokers aged more than 55 years along with liver & kidney tumors; thus offering huge potential markets for anti-cancer drug manufacturers investing in new product development programs targeting these age groups suffering from different types of cancers including hepatocellular carcinoma (HCC).
Regional Analysis:
North America dominated the global pancreatic cancer drugs market in 2017. This is attributed to the presence of key players, availability of newer generation drugs, high patient awareness levels and supportive government initiatives. For instance, in January 2015 Fycompa was resuming its distribution after a one-year suspension due to FDA approval for use under Special Protocol Assessment (SPA). The drug was approved for relapsed and refractory pediatric patients aged 6 years and above with Pancreatic Cancer. Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing healthcare expenditure levels by governments as well as private organizations coupled with rising prevalence rates of pancreatic cancer which has led it become one of the leading causes of death among all cancers types in this region.
Growth Factors:
- Increasing incidence of pancreatic cancer
- Rising demand for better and targeted therapies for pancreatic cancer
- Growing awareness about pancreatic cancer and its symptoms
- Technological advancements in the field of diagnosis and treatment of pancreatic cancer
- Availability of government funding for research on pancreatic cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Pancreatic Cancer Drugs Market Research Report
By Type
Drugs Approved for Pancreatic Cancer, Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, 5-FU (Fluorouracil Injection), Fluorouracil Injection, Gemcitabine Hydrochloride, Other
By Application
Hospitals, Clinics
By Companies
Eli Lilly and Company, Celgene, Roche, Novartis, Clovis Oncology, Amgen, Merck, Teva Pharmaceutical Industries, Pfizer, PharmaCyte Biotech, Eli Lilly and Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
192
Number of Tables & Figures
135
Customization Available
Yes, the report can be customized as per your need.
Global Pancreatic Cancer Drugs Market Report Segments:
The global Pancreatic Cancer Drugs market is segmented on the basis of:
Types
Drugs Approved for Pancreatic Cancer, Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, 5-FU (Fluorouracil Injection), Fluorouracil Injection, Gemcitabine Hydrochloride, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly and Company
- Celgene
- Roche
- Novartis
- Clovis Oncology
- Amgen
- Merck
- Teva Pharmaceutical Industries
- Pfizer
- PharmaCyte Biotech
- Eli Lilly and Company
Highlights of The Pancreatic Cancer Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Drugs Approved for Pancreatic Cancer
- Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
- Afinitor (Everolimus)
- Erlotinib Hydrochloride
- Everolimus
- 5-FU (Fluorouracil Injection)
- Fluorouracil Injection
- Gemcitabine Hydrochloride
- Other
- By Application:
- Hospitals
- Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pancreatic Cancer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pancreatic cancer drugs are medications that are used to treat pancreatic cancer. These drugs can help to shrink or stop the growth of the tumor, and may also help to improve the patient's overall health.
Some of the major companies in the pancreatic cancer drugs market are Eli Lilly and Company, Celgene, Roche, Novartis, Clovis Oncology, Amgen, Merck, Teva Pharmaceutical Industries, Pfizer, PharmaCyte Biotech, Eli Lilly and Company.
The pancreatic cancer drugs market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pancreatic Cancer Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pancreatic Cancer Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pancreatic Cancer Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pancreatic Cancer Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pancreatic Cancer Drugs Market Size & Forecast, 2018-2028
4.5.1 Pancreatic Cancer Drugs Market Size and Y-o-Y Growth
4.5.2 Pancreatic Cancer Drugs Market Absolute $ Opportunity
Chapter 5 Global Pancreatic Cancer Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Pancreatic Cancer Drugs Market Size Forecast by Type
5.2.1 Drugs Approved for Pancreatic Cancer
5.2.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
5.2.3 Afinitor (Everolimus)
5.2.4 Erlotinib Hydrochloride
5.2.5 Everolimus
5.2.6 5-FU (Fluorouracil Injection)
5.2.7 Fluorouracil Injection
5.2.8 Gemcitabine Hydrochloride
5.2.9 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Pancreatic Cancer Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Pancreatic Cancer Drugs Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pancreatic Cancer Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pancreatic Cancer Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Pancreatic Cancer Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Pancreatic Cancer Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Pancreatic Cancer Drugs Market Size Forecast by Type
9.6.1 Drugs Approved for Pancreatic Cancer
9.6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
9.6.3 Afinitor (Everolimus)
9.6.4 Erlotinib Hydrochloride
9.6.5 Everolimus
9.6.6 5-FU (Fluorouracil Injection)
9.6.7 Fluorouracil Injection
9.6.8 Gemcitabine Hydrochloride
9.6.9 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Pancreatic Cancer Drugs Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Pancreatic Cancer Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Pancreatic Cancer Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Pancreatic Cancer Drugs Market Size Forecast by Type
10.6.1 Drugs Approved for Pancreatic Cancer
10.6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
10.6.3 Afinitor (Everolimus)
10.6.4 Erlotinib Hydrochloride
10.6.5 Everolimus
10.6.6 5-FU (Fluorouracil Injection)
10.6.7 Fluorouracil Injection
10.6.8 Gemcitabine Hydrochloride
10.6.9 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Pancreatic Cancer Drugs Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Pancreatic Cancer Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Pancreatic Cancer Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Pancreatic Cancer Drugs Market Size Forecast by Type
11.6.1 Drugs Approved for Pancreatic Cancer
11.6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
11.6.3 Afinitor (Everolimus)
11.6.4 Erlotinib Hydrochloride
11.6.5 Everolimus
11.6.6 5-FU (Fluorouracil Injection)
11.6.7 Fluorouracil Injection
11.6.8 Gemcitabine Hydrochloride
11.6.9 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Pancreatic Cancer Drugs Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Pancreatic Cancer Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Pancreatic Cancer Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Pancreatic Cancer Drugs Market Size Forecast by Type
12.6.1 Drugs Approved for Pancreatic Cancer
12.6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
12.6.3 Afinitor (Everolimus)
12.6.4 Erlotinib Hydrochloride
12.6.5 Everolimus
12.6.6 5-FU (Fluorouracil Injection)
12.6.7 Fluorouracil Injection
12.6.8 Gemcitabine Hydrochloride
12.6.9 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Pancreatic Cancer Drugs Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Pancreatic Cancer Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Pancreatic Cancer Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Pancreatic Cancer Drugs Market Size Forecast by Type
13.6.1 Drugs Approved for Pancreatic Cancer
13.6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
13.6.3 Afinitor (Everolimus)
13.6.4 Erlotinib Hydrochloride
13.6.5 Everolimus
13.6.6 5-FU (Fluorouracil Injection)
13.6.7 Fluorouracil Injection
13.6.8 Gemcitabine Hydrochloride
13.6.9 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Pancreatic Cancer Drugs Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pancreatic Cancer Drugs Market: Competitive Dashboard
14.2 Global Pancreatic Cancer Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly and Company
14.3.2 Celgene
14.3.3 Roche
14.3.4 Novartis
14.3.5 Clovis Oncology
14.3.6 Amgen
14.3.7 Merck
14.3.8 Teva Pharmaceutical Industries
14.3.9 Pfizer
14.3.10 PharmaCyte Biotech
14.3.11 Eli Lilly and Company
